Trastuzumab With or Without Tamoxifen in Treating Women With Progressive Stage IV Breast Cancer
Status:
Withdrawn
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
RATIONALE: Monoclonal antibodies such as trastuzumab can locate tumor cells and either kill
them or deliver tumor-killing substances to them without harming normal cells. Estrogen can
stimulate the growth of breast cancer cells. Hormone therapy using tamoxifen may fight breast
cancer by blocking the uptake of estrogen. Combining trastuzumab with tamoxifen may kill more
tumor cells.
PURPOSE: Randomized phase III trial to compare the effectiveness of trastuzumab with or
without trastuzumab in treating women who have invasive stage IV breast cancer.